Gilead Sciences– tag –
-
Keymed Biosciences’ BCMA x CD3 Bispecific Antibody CM336 Advances to Phase II for Relapsed/Refractory Light Chain Amyloidosis, Secures $257M from Gilead’s Acquisition of Partner
BioSpace China Overview Keymed Biosciences announced its H1 2026 results and business updates, reporting that its BCMA x CD3 bispecific antibody, CM336, is progressing in a Phase II clinical trial for relapsed/refractory light chain amyl... -
FDA Approves Multiple Novel Oncology Drugs in June 2026, Including ADC for Breast Cancer and Combination for Prostate Cancer
Targeted Oncology USA Overview In June 2026, the U.S. FDA granted several new drug approvals and expanded indications in oncology, notably for Gilead Sciences' antibody-drug conjugate (ADC), sacituzumab govitecan-hziy (Trodelvy), in two ... -
FDA Approves Hepcludex, First Treatment for Chronic Hepatitis Delta Virus (HDV) Infection
FDA (Press Release), European AIDS Treatment Group USA Overview The U.S. FDA has approved Hepcludex (bulevirtide-gmod) injection as the first treatment for chronic hepatitis delta virus (HDV) infection in adults, with or without compensa...
1